Discover how the single-dose gene therapy market is transforming healthcare with curative therapies for rare and chronic genetic diseases. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Single-Dose Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Single-Dose Gene Therapy Market, by Therapy Type
8.1.1. In Vivo Gene Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Ex Vivo Gene Therapy
8.1.2.1. Market Revenue and Forecast
9.1. Single-Dose Gene Therapy Market, by Vector Type
9.1.1. AAV-based Vectors
9.1.1.1. Market Revenue and Forecast
9.1.2. Lentiviral Vectors
9.1.2.1. Market Revenue and Forecast
9.1.3. Retroviral Vectors
9.1.3.1. Market Revenue and Forecast
9.1.4. Non-Viral Vectors (plasmid, nanoparticle)
9.1.4.1. Market Revenue and Forecast
10.1. Single-Dose Gene Therapy Market, by Disease Area
10.1.1. Neuromuscular Disorders (e.g., SMA)
10.1.1.1. Market Revenue and Forecast
10.1.2. Ophthalmology (e.g., inherited retinal diseases)
10.1.2.1. Market Revenue and Forecast
10.1.3. Hematologic Disorders (e.g., Hemophilia A/B)
10.1.3.1. Market Revenue and Forecast
10.1.4. Metabolic Disorders (e.g., OTC deficiency, Fabry)
10.1.4.1. Market Revenue and Forecast
10.1.5. Cardiovascular Disorders
10.1.5.1. Market Revenue and Forecast
10.1.6. CNS Disorders (e.g., MLD, Batten disease)
10.1.6.1. Market Revenue and Forecast
10.1.7. Others (e.g., rare pediatric diseases)
10.1.7.1. Market Revenue and Forecast
11.1. Single-Dose Gene Therapy Market, by Patient Type
11.1.1. Pediatric (Largest)
11.1.1.1. Market Revenue and Forecast
11.1.2. Adult
11.1.2.1. Market Revenue and Forecast
12.1. Single-Dose Gene Therapy Market, by Route of Administration
12.1.1. Intravenous (IV)
12.1.1.1. Market Revenue and Forecast
12.1.2. Intrathecal (IT)
12.1.2.1. Market Revenue and Forecast
12.1.3. Subretinal (for ocular therapies)
12.1.3.1. Market Revenue and Forecast
12.1.4. Intramuscular / Localized Delivery
12.1.4.1. Market Revenue and Forecast
13.1. Single-Dose Gene Therapy Market, by End-User
13.1.1. Hospitals & Specialty Clinics (Largest)
13.1.1.1. Market Revenue and Forecast
13.1.2. Academic & Research Institutions
13.1.2.1. Market Revenue and Forecast
13.1.3. Contract Development & Manufacturing Organizations (CDMOs)
13.1.3.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Therapy Type
14.1.2. Market Revenue and Forecast, by Vector Type
14.1.3. Market Revenue and Forecast, by Disease Area
14.1.4. Market Revenue and Forecast, by Patient Type
14.1.5. Market Revenue and Forecast, by Route of Administration
14.1.6. Market Revenue and Forecast, by End-User
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Therapy Type
14.1.7.2. Market Revenue and Forecast, by Vector Type
14.1.7.3. Market Revenue and Forecast, by Disease Area
14.1.7.4. Market Revenue and Forecast, by Patient Type
14.1.8. Market Revenue and Forecast, by Route of Administration
14.1.8.1. Market Revenue and Forecast, by End-User
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Therapy Type
14.1.9.2. Market Revenue and Forecast, by Vector Type
14.1.9.3. Market Revenue and Forecast, by Disease Area
14.1.9.4. Market Revenue and Forecast, by Patient Type
14.1.10. Market Revenue and Forecast, by Route of Administration
14.1.11. Market Revenue and Forecast, by End-User
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Therapy Type
14.2.2. Market Revenue and Forecast, by Vector Type
14.2.3. Market Revenue and Forecast, by Disease Area
14.2.4. Market Revenue and Forecast, by Patient Type
14.2.5. Market Revenue and Forecast, by Route of Administration
14.2.6. Market Revenue and Forecast, by End-User
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Therapy Type
14.2.8.2. Market Revenue and Forecast, by Vector Type
14.2.8.3. Market Revenue and Forecast, by Disease Area
14.2.9. Market Revenue and Forecast, by Patient Type
14.2.10. Market Revenue and Forecast, by Route of Administration
14.2.10.1. Market Revenue and Forecast, by End-User
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Therapy Type
14.2.11.2. Market Revenue and Forecast, by Vector Type
14.2.11.3. Market Revenue and Forecast, by Disease Area
14.2.12. Market Revenue and Forecast, by Patient Type
14.2.13. Market Revenue and Forecast, by Route of Administration
14.2.14. Market Revenue and Forecast, by End-User
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Therapy Type
14.2.15.2. Market Revenue and Forecast, by Vector Type
14.2.15.3. Market Revenue and Forecast, by Disease Area
14.2.15.4. Market Revenue and Forecast, by Patient Type
14.2.16. Market Revenue and Forecast, by Route of Administration
14.2.16.1. Market Revenue and Forecast, by End-User
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Therapy Type
14.2.17.2. Market Revenue and Forecast, by Vector Type
14.2.17.3. Market Revenue and Forecast, by Disease Area
14.2.17.4. Market Revenue and Forecast, by Patient Type
14.2.18. Market Revenue and Forecast, by Route of Administration
14.2.18.1. Market Revenue and Forecast, by End-User
14.3. APAC
14.3.1. Market Revenue and Forecast, by Therapy Type
14.3.2. Market Revenue and Forecast, by Vector Type
14.3.3. Market Revenue and Forecast, by Disease Area
14.3.4. Market Revenue and Forecast, by Patient Type
14.3.5. Market Revenue and Forecast, by Route of Administration
14.3.6. Market Revenue and Forecast, by End-User
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Therapy Type
14.3.7.2. Market Revenue and Forecast, by Vector Type
14.3.7.3. Market Revenue and Forecast, by Disease Area
14.3.7.4. Market Revenue and Forecast, by Patient Type
14.3.8. Market Revenue and Forecast, by Route of Administration
14.3.9. Market Revenue and Forecast, by End-User
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Therapy Type
14.3.10.2. Market Revenue and Forecast, by Vector Type
14.3.10.3. Market Revenue and Forecast, by Disease Area
14.3.10.4. Market Revenue and Forecast, by Patient Type
14.3.11. Market Revenue and Forecast, by Route of Administration
14.3.11.1. Market Revenue and Forecast, by End-User
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Therapy Type
14.3.12.2. Market Revenue and Forecast, by Vector Type
14.3.12.3. Market Revenue and Forecast, by Disease Area
14.3.12.4. Market Revenue and Forecast, by Patient Type
14.3.12.5. Market Revenue and Forecast, by Route of Administration
14.3.12.6. Market Revenue and Forecast, by End-User
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Therapy Type
14.3.13.2. Market Revenue and Forecast, by Vector Type
14.3.13.3. Market Revenue and Forecast, by Disease Area
14.3.13.4. Market Revenue and Forecast, by Patient Type
14.3.13.5. Market Revenue and Forecast, by Route of Administration
14.3.13.6. Market Revenue and Forecast, by End-User
14.4. MEA
14.4.1. Market Revenue and Forecast, by Therapy Type
14.4.2. Market Revenue and Forecast, by Vector Type
14.4.3. Market Revenue and Forecast, by Disease Area
14.4.4. Market Revenue and Forecast, by Patient Type
14.4.5. Market Revenue and Forecast, by Route of Administration
14.4.6. Market Revenue and Forecast, by End-User
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Therapy Type
14.4.7.2. Market Revenue and Forecast, by Vector Type
14.4.7.3. Market Revenue and Forecast, by Disease Area
14.4.7.4. Market Revenue and Forecast, by Patient Type
14.4.8. Market Revenue and Forecast, by Route of Administration
14.4.9. Market Revenue and Forecast, by End-User
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Therapy Type
14.4.10.2. Market Revenue and Forecast, by Vector Type
14.4.10.3. Market Revenue and Forecast, by Disease Area
14.4.10.4. Market Revenue and Forecast, by Patient Type
14.4.11. Market Revenue and Forecast, by Route of Administration
14.4.12. Market Revenue and Forecast, by End-User
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Therapy Type
14.4.13.2. Market Revenue and Forecast, by Vector Type
14.4.13.3. Market Revenue and Forecast, by Disease Area
14.4.13.4. Market Revenue and Forecast, by Patient Type
14.4.13.5. Market Revenue and Forecast, by Route of Administration
14.4.13.6. Market Revenue and Forecast, by End-User
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Therapy Type
14.4.14.2. Market Revenue and Forecast, by Vector Type
14.4.14.3. Market Revenue and Forecast, by Disease Area
14.4.14.4. Market Revenue and Forecast, by Patient Type
14.4.14.5. Market Revenue and Forecast, by Route of Administration
14.4.14.6. Market Revenue and Forecast, by End-User
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Therapy Type
14.5.2. Market Revenue and Forecast, by Vector Type
14.5.3. Market Revenue and Forecast, by Disease Area
14.5.4. Market Revenue and Forecast, by Patient Type
14.5.5. Market Revenue and Forecast, by Route of Administration
14.5.6. Market Revenue and Forecast, by End-User
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Therapy Type
14.5.7.2. Market Revenue and Forecast, by Vector Type
14.5.7.3. Market Revenue and Forecast, by Disease Area
14.5.7.4. Market Revenue and Forecast, by Patient Type
14.5.8. Market Revenue and Forecast, by Route of Administration
14.5.8.1. Market Revenue and Forecast, by End-User
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Therapy Type
14.5.9.2. Market Revenue and Forecast, by Vector Type
14.5.9.3. Market Revenue and Forecast, by Disease Area
14.5.9.4. Market Revenue and Forecast, by Patient Type
14.5.9.5. Market Revenue and Forecast, by Route of Administration
14.5.9.6. Market Revenue and Forecast, by End-User
15.1. InfuCare Rx
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. BioScrip (now part of Option Care)
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Intramed Plus
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. AlayaCare
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. ContinuumRx
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. CareCentrix
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Healix Infusion Therapy
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Nufactor (a FFF Enterprises company)
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. PharMerica Infusion Services
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Infusion Associates
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description